PS
TLX

Principal Securities’s Telix Pharmaceuticals TLX Stock Holding History

Principal Securities’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21
Closed -$201 – 3669
2025
Q3 		$201 Hold
21
– – ﹤0.01% 3649
2025
Q2 		$337 Buy
+21
New +$353 ﹤0.01% 3542

Other funds holding TLX

PIC
Portland Investment Counsel Burlington, Ontario, Canada $312M AUM 53.32% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Principal Securities's TLX Position: Q4 2025 in Review

Principal Securities sold out of Telix Pharmaceuticals (TLX) in Q4 2025, closing a stake of 21 shares — an estimated $201 sold.

Principal Securities first reported a position in TLX in Q2 2025 and held it in 2 quarters. The position peaked at $337 in Q2 2025. 40 funds tracked by Wall St. Rank hold TLX as of Q4 2025.

  • Principal Securities reported no remaining Telix Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 21 Telix Pharmaceuticals shares in Q4 2025, an estimated $201.
  • Principal Securities first reported a position in Telix Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Principal Securities's Telix Pharmaceuticals position peaked at $337 in Q2 2025.
  • 40 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.